Company intelligence / Profile preview

ActoBio Therapeutics

Ownership: Private
Employees: ~20
Development stage: Phase 2

Overview

ActoBio Therapeutics has demonstrated positive interim results from its lead program AG019 in type 1 diabetes. In a Phase Ib/IIa study, both monotherapy and combination therapy with teplizumab stabilized key glycemic markers and showed immune modulation. The company’s approach leverages oral delivery of engineered bacteria to induce antigen-specific tolerance. Its celiac candidate AG017 received IND clearance but was later discontinued.[3][4][6]

Therapeutic areas: GastroenterologyOncologyEndocrinology
Modalities: Microbe-based therapeutics (engineered Lactococcus lactis)Recombinant biologics delivered orally/topically[1][3][4][6]Autologous CAR-T (in pipeline)[5]Recombinant LBP (in pipeline)[5]
Industry: Biotech

Drug pipeline

2 assets

AG011

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on ActoBio Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ActoBio Therapeutics.

Explore the full profile